November 28, 2023 Important Notice Regarding - VAPRISOL® (conivaptan hydrochloride) Injection Dear Valued Colleague, Due to the change in manufacturing sites Cumberland Pharmaceuticals Inc. has experienced a short-term outage of our branded product Vaprisol® (conivaptan hydrochloride) Injection. To support patient needs, we are collaborating with Nephron Sterile Compounding Center, LLC to provide a limited interim supply of their compounded drug product through their FDA registered Nephron 503B Outsourcing Facility. • Nephron’s 503B compounded drug product, Conivaptan Hydrochloride Injection Premixed in 5% Dextrose, 20 mg/100 mL (0.2 mg/mL), will be available in a single-dose IV bag containing 20 mg of conivaptan hydrochloride in 5% Dextrose in 100mL and will be sold in cases of 10 bags. • A limited interim supply of the 503B compounded conivaptan hydrochloride injection will be available until the branded product Vaprisol® is no longer on shortage. • The NDC for the 503B compounded drug product by Nephron is 69374-564-10. The compounded conivaptan hydrochloride injection is available through the Nephron 503B Outsourcing Facility. Please visit Nephron’s 503B outsourcing online ordering portal at cart.nephronsc.com to order the compounded conivaptan hydrochloride injection. You can contact the Nephron 503B Outsourcing Facility at nofaccounts@nephronpharm.com or call their Customer Service: 1-844-224-2225 to create a new account. Sincerely, Jim Herman Executive Vice President Cumberland Pharmaceuticals Inc.